Drug Profile

SSR 241586

Alternative Names: SSR241586

Latest Information Update: 17 Mar 2009

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator sanofi-aventis
Class Antidepressants; Antipsychotics; Anxiolytics; Irritable bowel syndrome therapies
Mechanism of Action Neurokinin 2 receptor antagonists; Neurokinin 3 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Discontinued Anxiety disorders; Irritable bowel syndrome; Major depressive disorder; Schizophrenia

17 Sep 2007 Phase-I clinical trials in Anxiety disorders in France (unspecified route)
17 Sep 2007 Phase-I clinical trials in Depression in France (unspecified route)
17 Sep 2007 Phase-I clinical trials in Irritable bowel syndrome in France (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com